保密 | 投資責任聲明 | 聯繫我們
Excorp Medical's Bioartificial Liver System comprises a reusable instrument, disposable tubing set and the proprietary, disposable bioartificail reactor.Once approved by regulatory agencies, Excorp Medical expects this breakthrough Bioartificial Liver System technology to be both live-saving and cost effective.Certain drugs or machines are available to substitute temporarily or long-term for many organs in the body…  no comparable substitute has been developed for the liver.The liver is the largest organ in the body and performs a variety of tasks impacting all body systems… as a result liver disease has widespread effects on virtually all other organs.Excorp Medical is currently the only company approved to conduct bioartificial liver human trials within the U.S.Currently patients must receive a liver transplant or endure prolonged hospitalization at great expense to have a chance at survival.Excorp Medical Bioartificial Liver System treatments serve as a bridge to liver regeneration and transplantExcorp Medical has developed a Bioartificial Liver System for the metabolic support of patients with compromised liver function.
Chinese Simplified
简体中文
Chinese Traditional
繁體中文
Arabic
若需更多資訊,請點擊下方按鈕

執行摘要
2009 年1 月

下載

愛克思科醫療設備有
限公司宣傳手冊

下載

美國食品及藥物管理局(FDA)之指定“孤兒”罕見病藥物所享權益

下載

致投資者


新聞
關聯單位
出版文章
臨床研究
招聘
致投資者

愛克思科醫療設備有限公司成立於1995 年11 月22 日,是一家總部位於美國,並在美國明尼
蘇達州註冊成立的公司 公司及其子公司的近期目標是:在急症肝功能衰竭患者肝臟自我修復,或肝臟移植手術成功之前, 為之提供有效,且性價比極高的臨時肝功能支援

本網站提供的資訊資料非完整資料,僅供參考;網站內容不包含與愛克思科醫療設備有限公司
投資相關的重要資訊及風險因素,公司可在不作通知的情況下對其進行更改

本網站所含所有資訊都與愛克思科醫療設備有限公司尋求投資無關。若有意進行投資,請參考
由愛克思科醫療設備有限公司編制,可代表公司決議的《私募備忘錄》《私募備忘錄》內容
包括本網站未包括的重要資訊,並可完全取代本網站所含所有資訊資料


©2014 Excorp Medical, Inc.